ZyVersa Therapeutics, Inc. (ZVSA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Weston, FL, 美国. 现任CEO为 Stephen C. Glover.
ZVSA 拥有 IPO日期为 2022-02-11, 7 名全职员工, 在 Other OTC, 市值为 $1.55M.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
